News & Insights

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. In this report we will be reviewing deal activity across 2022 and taking a look forward to see what 2023 may hold for the sector. We hope that you enjoy this report and look forward to discussing the data and underlying themes with […]

Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP).  IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios.  A pharma licensing deal […]

Welcome to our latest update on the outsourced Pharma Commercialisation Services sector.  As well as our usual update on M&A activity, this report takes a deep dive into one of the biggest challenges businesses are currently facing – the War for Talent. A phrase first coined by McKinsey in the late ’90s but one that […]

We are pleased to introduce you to the first of our regular sector updates on the outsourced pharma commercialisation sector.  For some time, CG Results Healthcare has been producing sector updates and whitepapers on the two other major areas pharmaceutical companies choose to outsource: manufacturing and research. This report focuses on commercialisation, encompassing Healthcare Marketing, […]

The last twelve months have been a time of extraordinary activity in the commercialisation sector – the COVID-19 pandemic saw medcomms groups play a crucial part in keeping pharma companies connected with patients and healthcare professionals, and dealmaking was frenetic on both sides of the Atlantic, for smaller agencies as well as for emerging ‘CCOs’. […]